论文部分内容阅读
目的观察经肝动脉灌注氟脲苷(FUDR)同时联合草酸铂(OXA)静脉化疗治疗肝转移癌的疗效及毒副反应。方法28例结直肠癌或胃癌肝转移患者,经肝动脉灌注FUDR,静脉输入OXA治疗2~6个周期。所有病例均行术前术后CT扫描评价治疗效果。随访44个月,评价疗效、生存期及毒副反应。结果总有效率为42.8%,中位生存时间(MST)为25个月,出现肝转移后的MST为15.5个月,1,2,3年生存率分别为89.3%、67.8%和25.0%。结论采用新的化疗方案FUDR加OXA局部联合全身同时化疗安全有效,患者生存期得以延长。
Objective To observe the curative effect and toxicity of transcatheter hepatic metastatic carcinoma via perfusion of hepatic artery with fludione (FUDR) and oxaliplatin (OXA) intravenous chemotherapy. Methods Twenty - eight patients with colorectal cancer or gastric cancer with liver metastasis were treated with hepatic artery perfusion with FUDR and intravenous OXA for 2 ~ 6 cycles. All cases underwent preoperative and postoperative CT scan to evaluate the therapeutic effect. Follow-up 44 months, evaluation of efficacy, survival and toxicity. Results The total effective rate was 42.8%. The median survival time (MST) was 25 months. The MST after hepatic metastasis was 15.5 months. The 1-, 2-, and 3-year survival rates were 89.3%, 67.8% and 25.0%, respectively. Conclusion The new chemotherapy regimen FUDR plus OXA local combined with systemic simultaneous chemotherapy is safe and effective, and patients’ survival time is prolonged.